



Evidence reviews

Evidence review

Published: 27 November 2024

www.nice.org.uk

The following documents contain the evidence that was used to develop the 2024 recommendations:

- A: accuracy and clinical and cost-effectiveness of spirometry for diagnosis of asthma
- B: accuracy and clinical and cost-effectiveness of bronchodilator response in the diagnosis of asthma
- <u>C: accuracy and clinical and cost-effectiveness of peak expiratory flow in the</u> diagnosis of asthma
- <u>D: accuracy and clinical and cost-effectiveness of skin prick test in children for diagnosis of asthma</u>
- <u>E: accuracy and clinical and cost-effectiveness of serum IgE measures in diagnosing</u> asthma in children
- F: accuracy and clinical and cost-effectiveness of FeNO in the diagnosis of asthma
- G: diagnostic accuracy of eosinophil blood count measures in the diagnosis of asthma
- H: bronchial challenge with histamine and methacholine for the diagnosis of asthma
- I: bronchial challenge test with mannitol
- J: bronchial challenge testing in response to exercise for the diagnosis of asthma
- <u>K: accuracy and clinical and cost-effectiveness of combination tests for diagnosis in people with suspected asthma</u>
- L: symptoms diary for monitoring asthma
- M: pulmonary function monitoring in asthma
- N: FeNO measures to monitor asthma
- O: risk stratified care for people with asthma
- P: drug classes for initial asthma management
- Q: drug combinations and sequencing for asthma management
- R: smart inhalers

The following document contains the evidence that was used to develop the 2020 recommendations:

Increasing ICS treatment within supported self-management for children and young people

The following documents contain the evidence that was used to develop the 2017 recommendations:

These documents preserve evidence reviews and committee discussions for areas of the guideline that were not updated in 2020.

- Full guideline for chronic asthma management
- Appendices A to S

These documents include the 2017 evidence reviews and committee discussions and have not been updated.

- Full guideline for asthma diagnosis and monitoring
- Appendices A to R

Other supporting evidence

- · Economic models
 - <u>Cost-utility analysis: Most cost-effective sequence or combination of tests to diagnose asthma</u>
 - Cost-utility analysis: Step-up therapy for management of uncontrolled asthma
- Methodology